Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next
Brunhilde Wirth, Mert Karakaya, Min Jeong Kye, et al.
Annual Review of Genomics and Human Genetics (2020) Vol. 21, Iss. 1, pp. 231-261
Closed Access | Times Cited: 206

Showing 26-50 of 206 citing articles:

A super minigene with a short promoter and truncated introns recapitulates essential features of transcription and splicing regulation of the SMN1 and SMN2 genes
Eric W. Ottesen, Joonbae Seo, Diou Luo, et al.
Nucleic Acids Research (2024) Vol. 52, Iss. 7, pp. 3547-3571
Open Access | Times Cited: 7
Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes
Natalia N. Singh, Shaine Hoffman, Prabhakara P. Reddi, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1867, Iss. 4, pp. 166063-166063
Open Access | Times Cited: 39
Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
Jacqueline Glascock, Basil T. Darras, Thomas O. Crawford, et al.
Journal of Neuromuscular Diseases (2023) Vol. 10, Iss. 5, pp. 937-954
Open Access | Times Cited: 16
Guideline “Motor neuron diseases” of the German Society of Neurology (Deutsche Gesellschaft für Neurologie)
Susanne Petri, Torsten Grehl, Julian Großkreutz, et al.
Neurological Research and Practice (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 15
The dynamic of changes of pNFH levels in the CSF compared with the motor scales’ scores during three years of nusinersen treatment in children with spinal muscular atrophy types 2 and 3
Mihaela Badina, Corina Sporea, Gabriel Cristian Bejan, et al.
Balneo and PRM Research Journal (2024) Vol. 15, Iss. Vol.15, no.1, pp. 643-643
Open Access | Times Cited: 6
Dysregulation of innate immune signaling in animal models of spinal muscular atrophy
Eric L. Garcia, Rebecca E. Steiner, Amanda C. Raimer, et al.
BMC Biology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene
Eric W. Ottesen, Ravindra Singh
Neuroscience Insights (2024) Vol. 19
Open Access | Times Cited: 5
Spinal muscular atrophy: Molecular mechanism of pathogenesis, diagnosis, therapeutics, and clinical trials in the Indian context
Ashutosh Aasdev, R S Sreelekshmi, V Rajesh Iyer, et al.
Journal of Biosciences (2024) Vol. 49, Iss. 1
Closed Access | Times Cited: 5
Administration of adipose-derived stem cells extracellular vesicles in a murine model of spinal muscular atrophy: effects of a new potential therapeutic strategy
Federica Virla, Ermanna Turano, Ilaria Scambi, et al.
Stem Cell Research & Therapy (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Epidemiology of Spinal Muscular Atrophy Based on the Results of a Large-Scale Pilot Project on 202,908 Newborns
Irina Yu. Efimova, Р. А. Зинченко, Andrey V. Marakhonov, et al.
Pediatric Neurology (2024) Vol. 156, pp. 147-154
Closed Access | Times Cited: 5
Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in Italy
Gianni Ghetti, Francesco Saverio Mennini, Andrea Marcellusi, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 9, pp. 687-701
Open Access | Times Cited: 5
Glucose and Lipid Metabolism Disorders in Adults with Spinal Muscular Atrophy Type 3
Marija Miletić, Zorica Stević, Svetlana Vujović, et al.
Diagnostics (2024) Vol. 14, Iss. 18, pp. 2078-2078
Open Access | Times Cited: 5
Clinical and radiological profile of patients with spinal muscular atrophy type 4
Paulo Victor Sgobbi de Souza, Wladimir Bocca Vieira de Rezende Pinto, Aracelly R.F. Ricarte, et al.
European Journal of Neurology (2020) Vol. 28, Iss. 2, pp. 609-619
Closed Access | Times Cited: 35
Mitochondrial defects in the respiratory complex I contribute to impaired translational initiation via ROS and energy homeostasis in SMA motor neurons
Maximilian Paul Thelen, Brunhilde Wirth, Min Jeong Kye
Acta Neuropathologica Communications (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 35
Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy
Yang-Jean Li, Tai‐Heng Chen, Yan-Zhang Wu, et al.
Nutrients (2020) Vol. 12, Iss. 12, pp. 3842-3842
Open Access | Times Cited: 33
SMN controls neuromuscular junction integrity through U7 snRNP
Sarah Tisdale, Meaghan Van Alstyne, Christian M. Simon, et al.
Cell Reports (2022) Vol. 40, Iss. 12, pp. 111393-111393
Open Access | Times Cited: 21
Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study
Claude Cancès, D. Vlodavets, Giacomo P. Comi, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 20
Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study
Hua Yang, Qiuji Tao, Dan Li, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice
Tai‐Heng Chen, Shih-Hsin Chang, Yu-Fu Wu, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 144-160
Open Access | Times Cited: 11
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
Umme Sabrina Haque, Toshifumi Yokota
Genes (2024) Vol. 15, Iss. 8, pp. 999-999
Open Access | Times Cited: 4
In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy
Kristine S. Ojala, Emily J. Reedich, Christine J. DiDonato, et al.
Brain Sciences (2021) Vol. 11, Iss. 2, pp. 194-194
Open Access | Times Cited: 26
Cathepsin D as biomarker in cerebrospinal fluid of nusinersen‐treated patients with spinal muscular atrophy
David Schorling, Heike Kölbel, Andreas Hentschel, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 7, pp. 2084-2096
Open Access | Times Cited: 19
An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy
Yueyi Li, Hongyu Zeng, Yuhao Wei, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 5-6, pp. 180-191
Closed Access | Times Cited: 10
Unraveling the genetic mysteries of spinal muscular atrophy in Chinese families
Shanshan Gao, Duo Chen, Qianqian Li, et al.
Orphanet Journal of Rare Diseases (2025) Vol. 20, Iss. 1
Open Access
An exploratory qualitative assessment of patient and clinician perspectives on patient-reported outcome measures and disease-modifying therapies in adults with spinal muscular atrophy
Jeremy Slayter, Lauren Casey, Shane McCullum, et al.
Journal of Rehabilitation Medicine (2025) Vol. 57, pp. jrm41254-jrm41254
Open Access

Scroll to top